Overview


According to FutureWise analysis, the market for Baculovirus Expression System is expected to grow with a CAGR of 8.7% over the forecast period 2023-2031, and reach a market value of US$ 0.76 billion by 2031.

The baculovirus expression system is a widely used method for producing large amounts of recombinant proteins in insect cells. It is prevalent for expressing proteins that are difficult to produce in bacterial or mammalian cells. The system utilizes a virus called baculovirus, which naturally infects insects like moths and butterflies. A specific type of baculovirus, often derived from Autographa californica multiple nucleopolyhedrovirus (AcMNPV), is chosen for the expression system. This virus has been extensively studied and engineered for this purpose. Scientists modify the baculovirus DNA by inserting the gene of interest (the gene that codes for the protein they want to produce) into the viral genome. This genetically modified virus is called a recombinant baculovirus. The recombinant baculovirus is then employed to infect insect cells, generally from the ovaries of the fall armyworm (Spodoptera frugiperda) or other insect cell lines. These cells serve as the protein production factories.

The baculovirus expression system is applied in various fields, including therapeutics, vaccines, and protein purification. The Baculovirus expression system produces various therapeutic proteins, including monoclonal antibodies, hormones, and growth factors. These proteins can be used for treating various diseases and conditions. Baculoviruses can be modified to deliver therapeutic genes to target cells. This is especially promising for genetic disorders and diseases that require specific gene-based treatments. Additionally, Baculoviruses are used to express and produce viral antigens for subunit vaccines. The expressed antigens can stimulate the immune system without using the whole pathogenic organism. Also, proteins expressed in the Baculovirus system can be purified for research or pharmaceutical use. This is especially valuable for proteins that are complex or hard to obtain through other expression systems.

FutureWise Market Research has published a report that provides an insightful analysis baculovirus expression system market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts baculovirus expression system market estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Thermo Fisher Scientific
  • Merck KGaA
  • Takara Bio
  • Agilent Technologies
  • Oxford Expression Technologies 
  • Promega Corporation
  • Qiagen N.V., Bio-Rad Laboratories 
  • New England Biolabs
  • Genscript Biotech Corporation 
  • Syngene International Limited
  • Sartorius AG
  • Aragen Bioscience
  • Vivopure
  • Creative Biogene
  • Absolute Antibody
  • Rockland Immunochemicals
  • Protein Technologies Inc.
  • Proteogenix
  • Virovek

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Baculovirus Expression System Market:

  • In February 2023, Thermo Fisher Scientific launched the BaculoDirect Baculovirus Expression System, a streamlined system for producing recombinant proteins in insect cells. The system includes a new vector, transferrin receptor-mediated transfection (TRMT) technology, and a new Sf9 insect cell line.
  • In April 2023, Promega Corporation launched the pFastBac Dual Baculovirus Expression System, a system for producing two recombinant proteins in insect cells from a single vector. The system includes a new vector, a new insect cell line, and a transfection reagent.

The increasing capacity of baculovirus expression systems to generate substantial quantities of recombinant proteins stands as a significant driver, particularly in industries reliant on large-scale protein production like pharmaceuticals and biotechnology. This proficiency addresses a critical need for these sectors, allowing the efficient production of therapeutic proteins, vaccines, and various biotechnological products. The high yields attained through this system significantly contribute to cost-effectiveness and scalability, making it an indispensable tool for meeting the demanding requirements of these vital industries, further fuels the growth of the market. Additionally, the insect-specific nature of baculoviruses presents them with a remarkable safety profile, rendering them harmless to humans, animals, and plants in the baculovirus expression system market. This exceptional quality is a major driver for their extensive pharmaceutical and biotech applications. It boosts confidence in researchers and production facilities, eliminating concerns about potential harm to living organisms. This safety assurance is of utmost importance, especially in developing therapeutics, vaccines, and biotechnological products, where stringent regulatory standards and product safety are paramount considerations. Therefore, baculovirus expression systems have become a cornerstone in these industries, facilitating the production of vital medical and biotechnological advancements. However, the complexity and time-intensive nature of scaling up production within baculovirus expression systems pose a significant restraint, especially for industries with high-demand requirements for recombinant proteins. The complex process of achieving large-scale production may lead to delays and resource-intensive efforts, potentially hindering the system's applicability in scenarios demanding swift and voluminous protein yields. Furthermore, the ever-evolving landscape of biotechnology and protein expression technologies presents a potential risk, as rapid advancements could render baculovirus systems obsolete if they fail to adapt and remain at par with industry standards. This necessitates a vigilant approach to innovation and adaptation within the field to ensure continued relevance and competitiveness. Therefore, hindering the market growth during the projection period.

By Product Type

  • Baculovirus
  • Expression Vector
  • Reagents
  • Others

By Application

  • Therapeutics
  • Vaccines
  • Protein Purification
  • Others

By End User

  • Biopharmaceutical Companies
  • Research Institutes
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Owing factors, including the increasing prevalence of chronic diseases, rising demand for protein therapeutics and vaccines, increasing R&D expenditure, government funding, and technological advancements in expression systems in the United States, are anticipated to propel market growth. In addition, the strong presence of leading biopharma companies, significant R&D investments, expanding applications in personalized medicines, collaboration and partnerships, and merger and acquisition are likely to drive the target market over the forecast period in the region. For instance, in April 2022, Thermo Fisher Scientific partnered with Watchmaker Genomics to improve AAV production for gene therapy using the Thermo Fisher Baculovirus Expression Vector System.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Baculovirus Expression System Market By Product Type, By Application, By End User, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1 Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2 Primary Data
              1.2.1. Key Data from Primary Sources
        3.Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Baculovirus Expression System Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Baculovirus Expression System Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Baculovirus Expression System Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Baculovirus Expression System Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Baculovirus
      2. Expression Vector
      3.  Reagents
      4. Others
  • 8.  Baculovirus Expression System Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Therapeutics
      2. Vaccines
      3. Protein Purification
      4. Others
  • 9.  Baculovirus Expression System Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Biopharmaceutical Companies
      2. Research Institutes
      3. Others
  • 10.  North America Baculovirus Expression System Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.  Latin America Baculovirus Expression System Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.  Europe Baculovirus Expression System Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.  Asia Pacific Baculovirus Expression System Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031  

  • 14.  Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 16.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
    •   1. Thermo Fisher Scientific
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Merck KGaA
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Takara Bio
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Agilent Technologies
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Oxford Expression Technologies 
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Promega Corporation
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Qiagen N.V., Bio-Rad Laboratories 
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. New England Biolabs
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. Genscript Biotech Corporation 
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Syngene International Limited
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. Sartorius AG
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           11.5. Strategic Overview
        12. Aragen Bioscience
           12.1. Company Overview
           12.2. Product Portfolio
           12.3. SWOT Analysis
           12.4. Financial Overview
           12.5. Strategic Overview
        13. Vivopure
           13.1. Company Overview
           13.2. Product Portfolio
           13.3. SWOT Analysis
           13.4. Financial Overview
           13.5. Strategic Overview
        14. Creative Biogene
           14.1. Company Overview
           14.2. Product Portfolio
           14.3. SWOT Analysis
           14.4. Financial Overview
           14.5. Strategic Overview
        15. Absolute Antibody
           15.1. Company Overview
           15.2. Product Portfolio
           15.3. SWOT Analysis
           15.4. Financial Overview
           15.5. Strategic Overview
        16. Rockland Immunochemicals
           16.1. Company Overview
           16.2. Product Portfolio
           16.3. SWOT Analysis
           16.4. Financial Overview
           16.5. Strategic Overview
        17. Protein Technologies Inc.
           17.1. Company Overview
           17.2. Product Portfolio
           17.3. SWOT Analysis
           17.4. Financial Overview
           17.5. Strategic Overview
        18. Proteogenix
           18.1. Company Overview
           18.2. Product Portfolio
           18.3. SWOT Analysis
           18.4. Financial Overview
           18.5. Strategic Overview
        19. Virovek
           19.1. Company Overview
           19.2. Product Portfolio
           19.3. SWOT Analysis
           19.4. Financial Overview
           19.5. Strategic Overview

  • 17.  Pre and Post COVID-19 Impact
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 18.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients